API Capecitabine Powder Purity Pharmaceutical Capecitabine Raw Material Powder Capecitabine

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Capecitabine
• Product Name: Capecitabine
• Appearance: White to off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anti-Cancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 154361-50-9
• Mf: C15h22fn3o6
• MW: 359.35
• Density: 1.49
• Melting Point: 110-121 C
• Boiling Point: 437.874 C at 760 Mmhg
• Refractive Index: 1.7
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 3 Ton/Month

Product Description

API Capecitabine Powder Purity Pharmaceutical Capecitabine Raw Material Powder Capecitabine

 

Product Description

Product Details

Product Name	Capecitabine
Appearance	white to off-white powder
CAS No.	154361-50-9
MF	C15H22FN3O6
MW	359.35

Capecitabine is an anti-metabolite fluoropyrimidine deoxynucleoside carbamate that can be converted into 5-FU in the body.It was developed by Roche and its trade name is Xeloda.It can inhibit cell division and interfere with RNA and protein.(protein) synthesis.Indicated for the further treatment of advanced primary or metastatic breast cancer that is refractory to paclitaxel and chemotherapy regimens including anthracyclines.Mainly used for the treatment of advanced primary or metastatic breast cancer, rectal cancer, colon cancer and gastric cancer.

Application & Function

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine is rapidly absorbed by the intestinal mucosa after oral administration, and then converted into an inactive intermediate 5'-deoxy-5' fluorocytidine in the liver by carboxyl esterase, followed by cytidine removal from liver and tumor tissues.The action of the aminoase is converted to 5'-deoxy-5' fluorouridine and finally catalyzed by thymidine phosphorylase to fluorouracil (5-FU) in tumor tissues.  Clinical studies have shown that the concentration of 5-FU in tumor tissue after oral administration is significantly higher than that of blood and muscle. The efficacy of tumors in a variety of animals was significantly higher than 5-FU.

Specification